To know about sickle cell disorder,
Get your copy of the book,
WE WILL SURVIVE (2nd Edition).
SICKLE CELL POEMS, PROSE, QUOTES, AND DIARIES.
At a discounted price of NGN1,000 or US$1,
Available on Selar as an ebook via this link
https://t.co/8vEmIBxDbO
To know about sickle cell disorder,
Get your copy of the book,
WE WILL SURVIVE (2nd Edition).
SICKLE CELL POEMS, PROSE, QUOTES, AND DIARIES.
At a discounted price of NGN1,000 or US$1,
Available on Selar as an ebook via this link
https://t.co/8vEmIBxDbO
Drive Change .... One donation at a time!
On May 9 from 8am to 6pm, donate blood at any Redan Service Station in Bulawayo, Masvingo, Kwekwe, Mutare or Harare and receive a fuel coupon as an appreciation.
Let's make a difference - One drop at a time!
Invite a friend
This paper from our Tanzania team & collaborators reports on the association of hydroxyurea response with genetic variants associated with fetal hemoglobin synthesis & drug metabolism. Article:https://t.co/8MrtYqiPRJ. Congrats to all authors &thanks to the study participants
How does the ASH SCD Away Elective make an impact? Hear from a past participant!
This one-month immersive rotation offers hands-on #SickleCellDisease training in both inpatient & outpatient care.
Apply now: https://t.co/TmYpyn3UFW
#hematology#SickleCell#SCD#MedTwitter
Did you know that digital tools can transform learning for children in underserved areas?
Let us support innovative education programmes and empower children with skills for the future, ensuring that no child is left behind in this digital age. #FutureSkills
Presenting right now at the inaugural Cell and Gene Therapy Symposium in Uganda is Prof. Julie Makani is from the Department of Haematology and Blood Transfusion at Muhimbili University of Health where 🇹🇿 established one of the world’s largest single-center study cohorts for SCD
200 million children across the world experience sexual violence.
Our vision and roadmap - produced in collaboration with sector leaders, practitioners and survivors - details how we can speed up our progress in ending this silent global epidemic.
As we await NICE’s approval decision on a new gene therapy for sickle cell, this video, featuring our CEO John James, provides insight into how the MHRA reached their decision on the treatment with valuable input from patients.